416 related articles for article (PubMed ID: 24123720)
1. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials.
Zhang Y; Hong J; Chi J; Gu W; Ning G; Wang W
Diabetes Metab Res Rev; 2014 Mar; 30(3):241-56. PubMed ID: 24123720
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
[TBL] [Abstract][Full Text] [Related]
3. Effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients with moderate to severe chronic kidney disease: Meta-analysis of randomized controlled trials using unadjusted data.
Yang M; Wang L; Gu L; Yuan W
J Diabetes; 2017 Dec; 9(12):1107-1117. PubMed ID: 28266136
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
Wu D; Li L; Liu C
Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
[TBL] [Abstract][Full Text] [Related]
5. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative.
Vashisht R; Jung K; Schuler A; Banda JM; Park RW; Jin S; Li L; Dudley JT; Johnson KW; Shervey MM; Xu H; Wu Y; Natrajan K; Hripcsak G; Jin P; Van Zandt M; Reckard A; Reich CG; Weaver J; Schuemie MJ; Ryan PB; Callahan A; Shah NH
JAMA Netw Open; 2018 Aug; 1(4):e181755. PubMed ID: 30646124
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data.
Bidulka P; Lugo-Palacios DG; Carroll O; O'Neill S; Adler AI; Basu A; Silverwood RJ; Bartlett JW; Nitsch D; Charlton P; Briggs AH; Smeeth L; Douglas IJ; Khunti K; Grieve R
BMJ; 2024 May; 385():e077097. PubMed ID: 38719492
[TBL] [Abstract][Full Text] [Related]
7. The benefits and risks of DPP4-inhibitors vs. sulfonylureas for patients with type 2 diabetes: accumulated evidence from randomised controlled trial.
Zhou JB; Bai L; Wang Y; Yang JK
Int J Clin Pract; 2016 Feb; 70(2):132-41. PubMed ID: 26709610
[TBL] [Abstract][Full Text] [Related]
8. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
[TBL] [Abstract][Full Text] [Related]
9. The long-term efficacy and safety of DPP-IV inhibitors monotherapy and in combination with metformin in 18,980 patients with type-2 diabetes mellitus--a meta-analysis.
Liu X; Xiao Q; Zhang L; Yang Q; Liu X; Xu L; Cheng W
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):687-98. PubMed ID: 24639059
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
[TBL] [Abstract][Full Text] [Related]
11. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis.
Salvo F; Moore N; Arnaud M; Robinson P; Raschi E; De Ponti F; Bégaud B; Pariente A
BMJ; 2016 May; 353():i2231. PubMed ID: 27142267
[TBL] [Abstract][Full Text] [Related]
12. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials.
Monami M; Cremasco F; Lamanna C; Marchionni N; Mannucci E
Diabetes Metab Res Rev; 2011 May; 27(4):362-72. PubMed ID: 21309062
[TBL] [Abstract][Full Text] [Related]
13. Direct head-to-head comparison of glycaemic durability of dipeptidyl peptidase-4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: A meta-analysis of long-term randomized controlled trials.
Chen K; Kang D; Yu M; Zhang R; Zhang Y; Chen G; Mu Y
Diabetes Obes Metab; 2018 Apr; 20(4):1029-1033. PubMed ID: 29095568
[TBL] [Abstract][Full Text] [Related]
14. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
Gooßen K; Gräber S
Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
[TBL] [Abstract][Full Text] [Related]
15. [The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials].
Guo XH; Feng ZK; Xu LH
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):588-594. PubMed ID: 28789492
[No Abstract] [Full Text] [Related]
16. A safety and tolerability profile comparison between dipeptidyl peptidase-4 inhibitors and sulfonylureas in diabetic patients: A systematic review and meta-analysis.
Farah D; Leme GM; Eliaschewitz FG; Fonseca MCM
Diabetes Res Clin Pract; 2019 Mar; 149():47-63. PubMed ID: 30710655
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis.
Foroutan N; Muratov S; Levine M
Clin Invest Med; 2016 Apr; 39(2):E48-62. PubMed ID: 27040861
[TBL] [Abstract][Full Text] [Related]
18. Short and medium-term efficacy of sodium glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized clinical trials.
Monami M; Liistro F; Scatena A; Nreu B; Mannucci E
Diabetes Obes Metab; 2018 May; 20(5):1213-1222. PubMed ID: 29327406
[TBL] [Abstract][Full Text] [Related]
19. Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Bae JH; Kim S; Park EG; Kim SG; Hahn S; Kim NH
Endocrinol Metab (Seoul); 2019 Mar; 34(1):80-92. PubMed ID: 30912341
[TBL] [Abstract][Full Text] [Related]
20. Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis.
Tricco AC; Antony J; Khan PA; Ghassemi M; Hamid JS; Ashoor H; Blondal E; Soobiah C; Yu CH; Hutton B; Hemmelgarn BR; Moher D; Majumdar SR; Straus SE
BMJ Open; 2014 Dec; 4(12):e005752. PubMed ID: 25537781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
